UNSPSC 51392507: Rimiterol hydrobromide

This classification denotes a beta-adrenergic agonist with the molecular formula C12H17NO3.BrH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I29DRR8S3R, chemically known as 1,2-benzenediol, 4-(hydroxy-2-piperidinylmethyl)-, hydrobromide, (r*,s*)- (9ci) but more generally known as rimiterol hydrobromide, which bears US NIH Compound Identifier 71409. European Medicines Agency schedules Rimiterol hydrobromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04251MIG.

UNSPSC 51392507 Rimiterol hydrobromide is a Commodity code that state and local health agencies are using to procure pharmaceutical products and related health system supplies, though recent solicitations show minimal direct alignment with the code's nominal scope. The Seminole County, Florida procurement (IFB60459723LAS, posted June 30, 2026, due July 26, 2026) sought naloxone and drug deactivation systems rather than rimiterol specifically, and the Texas Health and Human Services Commission RFI (HHS0017013, posted April 3, 2026) addressed direct-to-manufacturer prescription programs serving broader pharmacy benefit objectives. State and local issuing bodies applying this code include county health departments and state health commissions tasked with managing public health supplies, emergency response capabilities, and pharmacy benefit administration. The code shows limited recent activity with documented state and local procurement, and the few opportunities identified diverge substantially from rimiterol hydrobromide as a named product line.

Geographic activity clusters around Florida and Texas, where recent solicitations reflect demand for opioid antagonists (naloxone) and pharmacy supply-chain restructuring rather than rimiterol specifically. The Seminole County opportunity required quarterly deliveries of 1,900 naloxone units and 800 drug deactivation systems annually on a fixed-fee basis with an initial two-year term and one-year renewal option, while the Texas HHS RFI functioned as exploratory market research into direct-manufacturer contracting models prior to formal RFP issuance. No additional state or local rimiterol-specific opportunities appear in recent posting activity, suggesting the code sees negligible deployment for its nominal pharmaceutical product at the state and local procurement tier.